Who is sponsoring NCT04702399?

NCT04702399 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT04702399?

Interventions in NCT04702399: GEL GROUP.

What condition does NCT04702399 study?

NCT04702399 studies Patients With an Indication for Myomectomy or Polymyomectomy.

Is NCT04702399 still recruiting?

NCT04702399 is currently status unknown. Last updated 8 January 2021.

Last reviewed 2021-01-08 · How we verify

NCT04702399: PREVENDO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyaluronic Acid for the Prevention of Endocavitary Synechiae After Myomectomy

Status unknown NA Last updated 8 January 2021

What this trial tests

NA trial testing GEL GROUP in Patients With an Indication for Myomectomy or Polymyomectomy in 76 participants. Status unknown.

Timeline

1 February 2021

Primary endpoint
1 May 2022

1 May 2022

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	76
Start date	1 February 2021
Primary completion	1 May 2022
Estimated completion	1 May 2022

Drugs / interventions tested

GEL GROUP

Conditions studied

Patients With an Indication for Myomectomy or Polymyomectomy — all drugs for Patients With an Indication for Myomectomy or Polymyomectomy →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, female only, with Patients With an Indication for Myomectomy or Polymyomectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PREVENDO is a prospective, multicenter, pilot, and randomized study in 2 parallel arms and single blind, evaluating the proportion of endometrial synechiae 6 weeks after surgery in patients undergoing abdominal myomectomy or polymyomectomy, according to the application or not of an anti-adhesion gel (HYALOBARRIER® GEL ENDO)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04702399 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 8 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04702399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing